“The launch of Flyrcado represents a significant advancement in cardiac care, providing a new, highly effective diagnostic tool for those with known or suspected coronary artery disease,” said Eric Ruedinger, vice president and general manager of GE HealthCare’s Pharmaceutical Diagnostics segment for the U.S. and Canada. “With the grant of pass-through status by CMS, and the official commercial launch of Flyrcado, we are pleased that millions of patients throughout the U.S. will have access to this innovative technology, which will help improve diagnostic accuracy and may lead to better patient outcomes."

Flyrcado will be unveiled at ACC on Saturday, March 29, and throughout the conference, clinicians from several clinical trial and early adopter sites will participate in learning lab sessions, innovation stage talks, and 'Meet the Expert' breakout sessions to share their experiences and insights on using Flyrcado. You can learn more about these events and how to participate here.


Additional innovations highlighted at ACC 2025:

The latest version of CASE™ (Cardiac Assessment System for Stress Testing), powered by our CardioSoft™ technology, will be unveiled at ACC on Sunday, March 30. CASE is designed to enable clinicians to unlock insights quickly while ensuring seamless data flow, which could be critical for cardiac patients. The scalable portfolio provides on-demand access to high-quality ECG data and integrates into existing workflows. The advanced tools of CASE are aimed to support diverse cardiovascular disease patients, empower confident diagnosis and assist clinicians to promptly place patients on the appropriate care pathway.

CardIQ Suite is an integrated workflow for the seamless review of calcium scoring and cardiac computed tomography angiography (CCTA) data. The suite features a fully automated calcium scoring algorithm that quickly identifies calcium burden and location, providing both total and per territory scores within seconds, and includes the ability to visualize and estimate the volume of heart fat.vi Additionally, readers can immediately proceed to the CCTA read using advanced 2D and automated 3D processing tools as well as enjoy automated coronary segmentation and tracking AI algorithms to significantly reduce the need for manual intervention, enhancing efficiency with ready-to-read multi-planar images.

The recently introduced AltiX AI.i edition of Mac-Lab™, CardioLab™ and ComboLab™ editions aim to improve the user experience, elevate workflow in the cardiac catheterization lab and support even the most complex electrophysiology procedures. The AltiX AI.i edition of Mac-Lab, CardioLab and ComboLab is designed to enhance efficiency and precision care for multiple types of cardiac procedures. These latest editions offer new features that streamline workflow and enhance interoperability, while upholding strong cybersecurity standards. AltiX AI.i is available for order in the U.S. and is expected to launch in global markets later this year.vii

Back to HCB News

US Press Room Homepage